MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas

Avaniyapuram Kannan Murugan, Jianli Dong, Jingwu Xie, Mingzhao Xing

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Mitogen-activated protein kinase (MAPK) signaling pathway plays an important role in the pathogenesis of melanoma, colon cancer and thyroid cancer, which commonly harbor RAS and BRAF mutations. However, mutations in exon 2 of MEK1 and exon 7 of ERK2 have not been investigated in these cancers although they are occasionally found in some other cancers or cell lines. In this study, we performed mutational analysis to search for these mutations in 185 samples, including 167 tumor samples and 18 cell lines of melanoma, colon cancer and thyroid cancer. We found one MEK1 mutation in 1 of 37 (3%) melanoma tumor samples and another MEK1 mutation in 1 of 45 (2.2%) colon cancer samples. We did not find any MEK1 mutation in 99 thyroid tumor samples and 12 thyroid cancer cell lines. We also did not find any ERK2 mutation in melanoma, colon cancer and thyroid cancer. We thus report for the first time a low prevalence of MEK1 mutations in melanoma and colon cancer. Both of the two mutants have been demonstrated to be activating in the MAPK signaling pathway and may therefore provide potential target for effective therapy in cases of melanomas and colon cancer harboring these mutations.

Original languageEnglish (US)
Pages (from-to)2122-2124
Number of pages3
JournalCell Cycle
Volume8
Issue number13
StatePublished - Jul 1 2009

Fingerprint

Thyroid Neoplasms
Melanoma
Colon
Carcinoma
Colonic Neoplasms
Mutation
Neoplasms
Mitogen-Activated Protein Kinases
Cell Line
Exons
Thyroid Gland

Keywords

  • Colon cancer
  • ERK2 mutation
  • MEK1 mutation
  • Melanomas
  • Thyroid cancer

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. / Murugan, Avaniyapuram Kannan; Dong, Jianli; Xie, Jingwu; Xing, Mingzhao.

In: Cell Cycle, Vol. 8, No. 13, 01.07.2009, p. 2122-2124.

Research output: Contribution to journalArticle

Murugan, Avaniyapuram Kannan ; Dong, Jianli ; Xie, Jingwu ; Xing, Mingzhao. / MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. In: Cell Cycle. 2009 ; Vol. 8, No. 13. pp. 2122-2124.
@article{c3cd405225b74c06a143902a0e48d8f6,
title = "MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas",
abstract = "Mitogen-activated protein kinase (MAPK) signaling pathway plays an important role in the pathogenesis of melanoma, colon cancer and thyroid cancer, which commonly harbor RAS and BRAF mutations. However, mutations in exon 2 of MEK1 and exon 7 of ERK2 have not been investigated in these cancers although they are occasionally found in some other cancers or cell lines. In this study, we performed mutational analysis to search for these mutations in 185 samples, including 167 tumor samples and 18 cell lines of melanoma, colon cancer and thyroid cancer. We found one MEK1 mutation in 1 of 37 (3{\%}) melanoma tumor samples and another MEK1 mutation in 1 of 45 (2.2{\%}) colon cancer samples. We did not find any MEK1 mutation in 99 thyroid tumor samples and 12 thyroid cancer cell lines. We also did not find any ERK2 mutation in melanoma, colon cancer and thyroid cancer. We thus report for the first time a low prevalence of MEK1 mutations in melanoma and colon cancer. Both of the two mutants have been demonstrated to be activating in the MAPK signaling pathway and may therefore provide potential target for effective therapy in cases of melanomas and colon cancer harboring these mutations.",
keywords = "Colon cancer, ERK2 mutation, MEK1 mutation, Melanomas, Thyroid cancer",
author = "Murugan, {Avaniyapuram Kannan} and Jianli Dong and Jingwu Xie and Mingzhao Xing",
year = "2009",
month = "7",
day = "1",
language = "English (US)",
volume = "8",
pages = "2122--2124",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "13",

}

TY - JOUR

T1 - MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas

AU - Murugan, Avaniyapuram Kannan

AU - Dong, Jianli

AU - Xie, Jingwu

AU - Xing, Mingzhao

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Mitogen-activated protein kinase (MAPK) signaling pathway plays an important role in the pathogenesis of melanoma, colon cancer and thyroid cancer, which commonly harbor RAS and BRAF mutations. However, mutations in exon 2 of MEK1 and exon 7 of ERK2 have not been investigated in these cancers although they are occasionally found in some other cancers or cell lines. In this study, we performed mutational analysis to search for these mutations in 185 samples, including 167 tumor samples and 18 cell lines of melanoma, colon cancer and thyroid cancer. We found one MEK1 mutation in 1 of 37 (3%) melanoma tumor samples and another MEK1 mutation in 1 of 45 (2.2%) colon cancer samples. We did not find any MEK1 mutation in 99 thyroid tumor samples and 12 thyroid cancer cell lines. We also did not find any ERK2 mutation in melanoma, colon cancer and thyroid cancer. We thus report for the first time a low prevalence of MEK1 mutations in melanoma and colon cancer. Both of the two mutants have been demonstrated to be activating in the MAPK signaling pathway and may therefore provide potential target for effective therapy in cases of melanomas and colon cancer harboring these mutations.

AB - Mitogen-activated protein kinase (MAPK) signaling pathway plays an important role in the pathogenesis of melanoma, colon cancer and thyroid cancer, which commonly harbor RAS and BRAF mutations. However, mutations in exon 2 of MEK1 and exon 7 of ERK2 have not been investigated in these cancers although they are occasionally found in some other cancers or cell lines. In this study, we performed mutational analysis to search for these mutations in 185 samples, including 167 tumor samples and 18 cell lines of melanoma, colon cancer and thyroid cancer. We found one MEK1 mutation in 1 of 37 (3%) melanoma tumor samples and another MEK1 mutation in 1 of 45 (2.2%) colon cancer samples. We did not find any MEK1 mutation in 99 thyroid tumor samples and 12 thyroid cancer cell lines. We also did not find any ERK2 mutation in melanoma, colon cancer and thyroid cancer. We thus report for the first time a low prevalence of MEK1 mutations in melanoma and colon cancer. Both of the two mutants have been demonstrated to be activating in the MAPK signaling pathway and may therefore provide potential target for effective therapy in cases of melanomas and colon cancer harboring these mutations.

KW - Colon cancer

KW - ERK2 mutation

KW - MEK1 mutation

KW - Melanomas

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=67650531876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650531876&partnerID=8YFLogxK

M3 - Article

C2 - 19411838

AN - SCOPUS:67650531876

VL - 8

SP - 2122

EP - 2124

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 13

ER -